Proteasome inhibition and Parkinson's disease modeling

Jordi Bové, Chun Zhou, Vernice Jackson-Lewis, Julie Taylor, Yaping Chu, Hardy J. Rideout, Du Chu Wu, Jeffrey H. Kordower, Leonard Petrucelli, Serge Przedborski

Research output: Contribution to journalArticle

115 Scopus citations

Abstract

Impaired proteasome function is a potential mechanism for dopaminergic neuron degeneration. To model this molecular defect, we administered systemically the reversible lipophilic proteasome inhibitor, carbobenzoxy-L-isoleucyl-γ-t-butyl-L-glutamyl-L-alanyl-L-leucinal (PSI), to rodents. In contrast to a previous report, this approach failed to cause any detectable behavioral or neuropathological abnormality in either rats or mice. Although theoretically appealing, this specific model of Parkinson's disease appears to exhibit poor reproducibility.

Original languageEnglish (US)
Pages (from-to)260-264
Number of pages5
JournalAnnals of neurology
Volume60
Issue number2
DOIs
StatePublished - Aug 2006

ASJC Scopus subject areas

  • Neurology
  • Clinical Neurology

Fingerprint Dive into the research topics of 'Proteasome inhibition and Parkinson's disease modeling'. Together they form a unique fingerprint.

  • Cite this

    Bové, J., Zhou, C., Jackson-Lewis, V., Taylor, J., Chu, Y., Rideout, H. J., Wu, D. C., Kordower, J. H., Petrucelli, L., & Przedborski, S. (2006). Proteasome inhibition and Parkinson's disease modeling. Annals of neurology, 60(2), 260-264. https://doi.org/10.1002/ana.20937